SSShivani Saraf

Shivani Saraf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shivani Saraf has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Review on the Recent Advancements and Artificial Intelligence in Tablet Technology

    by Amit Sahu, Sunny Rathee, Shivani Saraf, Sanjay K. Jain

    Background:: Tablet formulation could be revolutionized by the integration of modern technology and established pharmaceutical sciences. The pharmaceutical sector can develop tablet formulations that are not only more efficient and stable but also patient-friendly by utilizing artificial intelligence (AI), machine learning (ML), and materials science. Objectives:: The primary objective of this review is to explore the advancements in tablet technology, focusing on the integration of modern technologies like artificial intelligence (AI), machine learning (ML), and materials science to enhance the efficiency, cost-effectiveness, and quality of tablet formulation processes. Methods:: This review delves into the utilization of AI and ML techniques within pharmaceutical research and development. The review also discusses various ML methodologies employed, including artificial neural networks, an ensemble of regression trees, support vector machines, and multivariate data analysis techniques. Results:: Recent studies showcased in this review demonstrate the feasibility and effectiveness of ML approaches in pharmaceutical research. The application of AI and ML in pharmaceutical research has shown promising results, offering a potential avenue for significant improvements in the product development process. Conclusion:: The integration of nanotechnology, AI, ML, and materials science with traditional pharmaceutical sciences presents a remarkable opportunity for enhancing tablet formulation processes. This review collectively underscores the transformative role that AI and ML can play in advancing pharmaceutical research and development, ultimately leading to more efficient, reliable and patient-centric tablet formulations.


  • Emerging Approaches for the Treatment of Rheumatoid Arthritis: An Outlook

    by Priyanka Kumari, Sanjay K. Jain, Shivani Saraf, Ankita Tiwari, Pritish Panda, Amit Verma

    Background: Rheumatoid arthritis (RA) is an inflammatory disease that causes pannus formation, thickened synovium, joint bone reabsorption, and acute impairment, and increases the death rate. Many people with RA now live better lives as a result of recent improvements in treatment, which have dramatically slowed the disease's course. However, a significant portion of patients continue to either be non-responsive to existing treatments or have developed a resistance to them. Nanotechnology is becoming a more and more intriguing tool for investigating novel strategies, ranging from treating various disease states to tackling complicated conditions. Objective: The primary goal of the work was to outline the research activities on versatile nanocarriers, like polymeric micelles, nanoparticles, liposomes, etc., with controlled/sustained drug release patterns fabricated to elevate the effectiveness of drug delivery. Methods: This review mainly focuses on emerging strategies to deliver various nanocarriers encapsulating anti-rheumatic drugs, enzymes, genes, phytoconstituents, etc. It also includes upto- date progress regarding patents and clinical trials filed for the treatment of RA. Results: In most of the recent studies, nanocarrier-based drug delivery has gained attention worldwide and led to the development of new approaches for treating RA. A better understanding of pathophysiology and signalling pathways helps to select the antirheumatic drug. The encapsulation of active moiety into the novel nanocarrier enhances the solubility of insoluble drugs. It restricts the exposure of the drug to the non-inflamed site using various targeting strategies, like active, passive, or biomimetic targeting and stimuli-responsive carrier systems to enhance the drug delivery mechanism. Conclusion: A brief description of current RA treatments using nanocarrier technology is provided in this paper, along with predictions for potential enhancements to the nanotherapeutic regimen.


  • Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape

    by Sarjana Raikwar, Ankit Jain, Shivani Saraf, Pooja Das Bidla, Pritish Kumar Panda, Ankita Tiwari, Amit Verma, Sanjay K. Jain

    Breast carcinoma (BC) is one of the most frequent causes of cancer-related death among women, which is due to the poor response to conventional therapy. There are several complications associated w...


  • Application Potential of Pectin in Drug Delivery

    by Pritish Kumar Panda, Gaytri Gour, Shivani Saraf, Ankita Tiwari, Amit Verma, Ankit Jain, Sanjay K. Jain

    Pectin, a naturally occurring, biodegradable heteropolysaccharides, comprised of (1,4)-linked α-d-galacturonic acid entities and numerous neutral sugars like D-galactose, L-arabinose, and D-xylose, etc., has grabbed the attention of scientists in last few years because of its biodegradability, biocompatibility, and non-toxicity. It has found promising applications in an arena of drug delivery and biomedical field. On the basis of its degree of esterification (DE), it has been classified into two major groups, i.e., low methoxy pectin (LMP) and high methoxyl pectin (HMP). The pectin chains combine to form the three-dimensional frameworks leading to the formation of a gel. The pectin properties can be enhanced and chemically altered to form composites, blends for a multiplicity of pharmaceutical applications. It has been utilized potentially as a polymer for targeted drug delivery. This chapter deals with the application potential of pectin in the development of drug delivery systems.